标题：A Retrospective Analysis of the Effect of Tigecycline on Coagulation Function
作者：Leng, Bing; Xue, Yuan Chao; Zhang, Wen; Gao, Tian Tian; Yan, Gen Quan; Tang, Hui
作者机构：[Leng, Bing; Zhang, Wen; Gao, Tian Tian; Yan, Gen Quan; Tang, Hui] Shandong Univ, Shandong Prov Hosp, Dept Pharm, 324 Jingwu Rd, Jinan 250021, Shandon 更多
通讯作者：Tang, H;Tang, H;Tang, H
通讯作者地址：[Tang, H]Shandong Univ, Shandong Prov Hosp, Dept Pharm, 324 Jingwu Rd, Jinan 250021, Shandong, Peoples R China;[Tang, H]Univ British Columbia, Ctr Hea 更多
来源：CHEMICAL & PHARMACEUTICAL BULLETIN
关键词：tigecycline; coagulation parameter; retrospective analysis; infection;; assess
摘要：A number of clinical trials demonstrated that tigecycline was effective and well tolerated in the treatment of patients with various bacterial infections, but few literatures had shown the coagulopathy induced by tigecycline. To address this concern, we performed a retrospective analysis to assess the impact of tigecycline treatment on coagulation parameters in 50 patients with bacterial infections in our hospital (Shandong Provincial Hospital, China). These patients were treated with tigecycline at Shandong Provincial Hospital in 2015-2016 at either a recommended (50 mg q12h) or a higher dose (100 mg q12h). Coagulation parameters, including Fibrinogen (FIB) levels, prothrombin time (PT), activated partial thromboplastin time (aPTT), platelet count (PLT) and D-dimer, were evaluated in order to assess the impact of tigecycline treatment in these severely infected patients. What we found was that the plasma fibrinogen (FIB) level was 4.63 +/- 1.56 g/L before tigecycline treatment, and decreased to 2.92 +/- 1.23 g/L during treatment, which was statistically significant (p < 0.001). The mean values of aPTT and PT were significantly increased from 39.58 +/- 8.72 to 44.05 +/- 10.45s (p = 0.002), and from 15.37 +/- 1.53 to 16.37 +/- 2.64 s (p = 0.004), respectively. This study demonstrates that treatment of tigecycline could reduce FIB, prolong aPTT and PT. In conclusion, we advise that it is necessary for practitioners routinely monitor coagulation level in at-rick patient populations treated with tigecycline.